Clinical trial
Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00293696 · Tampere University, Other · Completed
Key facts
| NCT number | NCT00293696 |
|---|---|
| Title | Casodex/Zoladex Biomarkers in Localised Prostate Cancer |
| Official title | A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma |
| Lead sponsor | Tampere University, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | bicalutamide (Casodex), goserelin (Zoladex) |
| Enrollment | 30 |
| Start date | Oct 1, 2004 |
| Completion | Nov 1, 2006 |
| First posted | Feb 17, 2006 |
| Last update posted | May 8, 2007 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: